These biomarkers can detect the presence of a disease, as well as monitor its progress and the effectiveness of treatment
From the paper - seems like there's applicability of this method to other diseases:
"Cytochrome P450s (CYPs, P450s) are major drug-metabolizing enzymes that participate in phase I reactions as monooxygenases
5,
6. Substrates of P450s vary from endogenous to exogenous chemicals, and more than 3,000 substrates of P450s are known to exist
7. The expression levels of P450s change under inflammatory conditions
8. Under these conditions, proinflammatory cytokines such as interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor α (TNFα) regulate the expression of P450s via certain nuclear receptors or transcription factors such as nuclear factor-κB (NF-κB)
8. In inflammatory diseases such as cancer
9, cardiovascular disease
10, diabetes
11,
12 and ulcerative colitis
13,
14, the expression of P450s differs from that in a disease-free state. Moreover, these changes in P450s vary among diseases
9,
10"
"We observed significant differences in inhibition rates for three P450s (Fig.
6). The inhibition rate associated with CYP1A1 was significantly lower than that of the control (6.4% and 17.0%, respectively). The inhibition rate associated with CYP2C8 was also lower than that of the control (83.9% and 87.0%, respectively). The inhibition rate associated with CYP3A5 was lower than that of the control (60.5% and 67.6%, respectively). In contrast, the inhibition rates associated with other P450s (CYP1A2, CYP2A13, CYP2B6, CYP2C9, CYP2C18, CYP2C19, CYP2E1, and CYP3A4) were not significantly different.'
